Drugs / MUC1
MUC1
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00374049 | Jun 2006 → Jan 2008 | prostate cancer | Olivera Finn | Completed | No outcome recorded |
| Phase 1 | NCT00003761 | Mar 1999 → Apr 2001 | breast cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05419011 | May 2023 → Jul 2027 expected | Lynch syndrome, colorectal carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00773097 | Oct 2008 → Oct 2011 | — | Robert Schoen | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-11-10 | Cellectis S.A. | Results Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022 cellectis.com ↗
MUC-1 CAR T-cells infiltrate tumors more efficiently and extend survival when enhanced with attributes catered towards the tumor microenvironment (TME) of TNBC tumors. |
| 2003-10-20 | Eckert & Ziegler Radiopharma GmbH | Results NEMOD Demonstrates Promising Preclinical Anti-Cancer Results for PankoMab(TM) ezag.com ↗
Strong anti-tumour activity was observed in 90Y-PankoMab(TM) treated animals. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-11-10 | Cellectis S.A. | Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022 cellectis.com ↗ |
| 2003-10-20 | Eckert & Ziegler Radiopharma GmbH | NEMOD Demonstrates Promising Preclinical Anti-Cancer Results for PankoMab(TM) ezag.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MUC1 | “MUC-1 vaccine (100ug) admixed with GM-CSF (100ug), administered subcutaneously” NCT00374049 ↗ |
| Known as | Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05419011 ↗ |
| Known as | recombinant vaccinia DF3/MUC1 vaccine | “recombinant vaccinia DF3/MUC1 vaccine (rV-DF3/MUC1)” NCT00003761 ↗ |
| Known as | rV-DF3/MUC1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003761 ↗ |
| Action | Deplete | “may cause the immune system to develop a defense against cancer that recognizes and destroys any precancer and cancer cells that produce these proteins in the future.” NCT05419011 ↗ |
| Modality | Vaccine | “recombinant vaccinia DF3/MUC1 vaccine” NCT00003761 ↗ |
| Route | Other | “Patients receive recombinant vaccinia DF3/MUC1 vaccine (rV-DF3/MUC1) intradermally.” NCT00003761 ↗ |